Doctors can often identify signs of a melanoma through a visual examination of a patient’s skin, by using a dermoscope or other tools. But additional information is sometimes needed to make a precise diagnosis, according to SciBase, a medical tech company based in Stockholm, Sweden—which has developed a device it says provides exactly that.
The device, called Nevisense, uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. SciBase says the method has been proven “in the world’s largest melanoma detection study of its kind,” and is “the only FDA-approved test for early melanoma detection at point-of-care.”
Today SciBase announced that it’s partnering with North Texas-based Bare Dermatology—which has five offices in the Dallas area—to pilot the device at select locations. Headquartered in Aubrey north of Dallas-Fort Worth, Bare Dermatology was founded in 2022.
Dr. Aaron Farberg, chief medical officer of Bare Dermatology, said the device “can help us to identify melanoma at an early stage, which is critical for improving patient outcomes.”
“Melanoma is a leading cause of death among skin cancers, but when detected early, it has a nearly 100% cure rate,” Farberg added in a statement.
Pia Renaudin, who was recently appointed CEO of SciBase and is based in Sweden, said her company is focused on “addressing the need for early melanoma detection in the highest at-risk patient population in the U.S.”
“We’re expanding in the areas where melanoma rates are high,” Renaudin said of the Texas and Florida markets, where Nevisense is also being piloted. “We’re pleased to collaborate with Bare Dermatology as we expand across the U.S. to address the early detection of melanoma needs.”
When diagnosing and treating melanoma, “timing is critical,” SciBase says on the company’s website. “If detected and treated early, a melanoma is largely curable. Nevisense gives your doctor immediate objective information, making it possible to quickly determine which steps are needed in your treatment.”
By providing objective diagnostic data, the company says, its device “helps doctors to make better and more accurate decisions about diagnosis and treatment in difficult cases. This ability to accurately measure your mole can reduce the need for unnecessary mole removals as well as the risk of leaving a potential melanoma undetected.”
Get on the list.
Dallas Innovates, every day.
Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.